U.S. pharma big copyright scrapped two experimental weight loss tablets past 12 months—a after-daily tablet, lotiglipron, on account of elevated liver enzymes as well as a twice-everyday tablet, danuglipron, as a result of strong Unwanted side effects—but CEO Albert Bourla has said the company is set to “Participate in and earn” during the